Navigation Links
Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
Date:6/9/2009

logies and is yet another important step in our establishment of a fully integrated and highly innovative package of biopharmaceutical development capabilities” says Menzo Havenga, Managing Director of Biosciences at TNO.


About Amarna Therapeutics
Amarna Therapeutics B.V. is a Biotechnology company that develops therapeutic vaccinations to treat immunity-associated diseases including autoimmune diseases, allergies and cancer and gene therapies to treat genetic disorders. The base of Amarna’s therapeutics is the SVac viral gene delivery vector platform, which provides sensational characters unheard of in the Pharma arena, creating opportunities to serve markets with enormous potential due to clinical unmet needs.

About SVac
Our SVac viral gene delivery vector platform has a number of unique properties compared to other viral gene delivery vectors such as lentiviral, poxviral, alphaviral, adenoviral and adeno-associated virus (AAV) vector systems. SVac is non-immunogenic in humans, highly stable, safe to use and can be cost effectively produced in large amounts in a proprietary producer cell line denoted SuperVero. Moreover, the vector has extensively been tested for safety in model animals. The SuperVero cell line has been qualified and tested using Quality Control (QC) assays and its use for manufacturing clinical trial material has been validated. The whole vector production process is similar to the current manufacturing processes of the polio, rabies and influenza virus vaccines in which a master seed virus is seeded to producer cells in large fermentors. Because of its immunological inertia in man SVac is the only vector system known that is suitable for for treating genetic disorders and immunity associated diseases.

'/>"/>

b3c newswire

Page: 1 2 3

Related biology news :

1. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
2. NIH announces new program to develop therapeutics for rare and neglected diseases
3. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
4. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
5. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
6. A novel target for therapeutics against Staph infection
7. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
8. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
9. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
10. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics
11. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... . To date, ... overdoses, doctors are often limited to supportive therapy such as ... combination of drugs involved. So what can be done if ... ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences ... question. "The task was to develop an agent that could ...
(Date:10/16/2014)... Researchers at William and Mary,s Virginia Institute of ... from the Environmental Protection Agency to identify the ... and to develop tools to help local governments ... project depends critically on a dataset of tidal-marsh ... 1970s. Only with this historical baseline can today,s ...
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... infectious diseases are urgently needed in resource-limited countries. ... Academy of Microbiology colloquium, "Bringing the Lab to ... Settings," describes the challenges inherent in bringing new ... the world where they are needed most. Point-of-care ...
... team of UC Davis investigators has found that a genetic ... prostate cancer. The mutation of the so-called p53 (or Tp53) ... now has never been shown to act as an initiating ... treating the disease. The study was published online ...
... one of the few probiotics with medical food designation for ... of more than 80 studies that have demonstrated its use ... ileal pouch. Ulcerative colitis patients, in particular, have been shown ... drug regimen. One particular study shows that the combination of ...
Cached Biology News:Report addresses challenges in implementing new diagnostic tests where they are needed most 2UC Davis scientists find new role for P53 genetic mutation -- initiation of prostate cancer 2By adding VSL#3 probiotic to traditional therapies UC patients can improve remission rates 2
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... October 22, 2014 WriteResult, LLC ... – has been working with a team of researchers ... Haven Farms Community Farming Collaborative to provide electronic questionnaire ... The study, which started in May, aims to ... provides participants weekly exposure to and participation in urban ...
(Date:10/22/2014)...   Synthetic Biologics, Inc. (NYSE MKT: SYN), ... infections and diseases, announced today that the U.S. Patent ... for a composition of matter patent application that covers ... SYN-004. This is Synthetic Biologics, first allowed patent application ... to the Company,s extensive C. difficile patent ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
... Medarex, Inc. (Nasdaq: MEDX ) announced today ... J.P. Morgan Healthcare Conference at 8:30 a.m. Pacific Time (11:30 ... will be webcast live and will be available in the ... . An archived edition of the presentation will be available ...
... PCYC ) today announced that in ... Associates ("RWD") made an unsecured loan to,Pharmacyclics, Inc. ... $5,000,000. As of,December 31, 2008, the company,s ... the $5,000,000 in loan proceeds. RWD,is controlled ...
... Jan. 6 Omeros Corporation today announced that The ... grant against milestones to support the Company,s collaboration with ... a new target for the treatment of Parkinson,s disease. ... disease, Omeros is the first to link its novel ...
Cached Biology Technology:Medarex to Present at the 27th Annual J.P. Morgan Healthcare Conference 2Pharmacyclics Secures $5.0 Million in Debt Financing 2Pharmacyclics Secures $5.0 Million in Debt Financing 3Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 2Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target 3
Rabbit polyclonal to Quinolinic acid ( Abpromise for all tested applications). Antigen: Synthetic quinolinic acid conjugated to bovine serum albumin....
Human Cell Line Slides...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile...
Mouse Cell Line Slides...
Biology Products: